



Gilead-initiated or Gilead-supported Abstracts Published at IAS 2023

Abstracts selected by Gilead Medical Affairs Germany, July 17th



21AS 2023

Gilead Internal Datasets: IAS 2023

Abstracts selected by Gilead Medical Affairs Germany, July 17th





	B/F/TAF				
Oral / Poster	Presenter	Title	Session Information	Link to Session	
Oral	Marathe, D	PHARMACOKINETICS, SAFETY, AND EFFICACY OF B/F/TAF IN VIROLOGICALLY SUPPRESSED PREGNANT WOMEN WITH HIV	Mon, Jul 24 16:19-16:27 Plaza Auditorium		
E-poster (LB) LBEPB13	Avihingsanon, A	WEEK 96 RESULTS OF ALLIANCE, A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING BICTEGRAVIR/EMTRICITABINE/TENOFOVI R ALAFENAMIDE (B/F/TAF) VERSUS DOLUTEGRAVIR + EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (DTG+F/TDF) IN TREATMENT-NAÏVE HIV-1/HEPATITIS B (HBV) COINFECTION	Virtual		





LENACAPAVIR (LEN, FORMERLY GS-6207)				
Oral / Poster	Presenter	Title	Session Information	Link to Session
Oral OAB0205	Ogbuagu, O	LENACAPAVIR ORAL BRIDGING (300 MG QW) MAINTAINS EFFICACY WITH A SIMILAR SAFETY PROFILE WHEN SC LEN CANNOT BE ADMINISTERED	Tues, Jul 25 15:12-15:20 Plaza Ballroom	
Poster Exhibition TUPEB07	Singh, R	PHARMACOKINETIC BRIDGING WITH ORAL LENACAPAVIR FOR MISSED SUBCUTANEOUS Q6M DOSING	Tues, Jul 25 12:00-13:00 Poster Exhibition area	
E-poster EPB0216	Castagna, A	PATIENT-REPORTED OUTCOMES FROM THE CAPELLA CLINICAL TRIAL OF HEAVILY TREATMENT-EXPERIENCED ADULTS LIVING WITH HIV	Virtual	
E-poster EPE0832	Herbst, A	HEALTHCARE PROVIDER EXPERIENCE OF ADMINISTERING LONG-ACTING LENACAPAVIR FOR PEOPLE WITH HIV WITH HEAVY TREATMENT EXPERIENCE ENGAGED THROUGH A COMPASSIONATE USE PROGRAM IN THE UNITED STATES	Virtual	
E-poster TUPEB14	Singh, R	RECOMMENDATIONS FOR MISSED ORAL LENACAPAVIR LOADING DOSES USING POPULATION-PHARMACOKINETICS-BASED SIMULATIONS	Tues, Jul 25 12:00-13:00 Poster Exhibition area	
E-poster EPB0230	Shaik, N	COMPARISON OF LONG-ACTING LENACAPAVIR PHASE 2/3 REGIMEN VS SIMPLIFIED REGIMEN USING POPULATION-PK ANALYSIS AND SIMULATION	Virtual	



PEDIATRICS				
Oral / Poster	Presenter	Title	Session Information	Link to Session
E-poster EPB2036	Rahkmanina, N	LONGITUDINAL LYMPHOCYTE DYNAMICS IN VIROLOGICALLY SUPPRESSED CHILDREN WITH HIV INITIATING SINGLE-TABLET E/C/F/TAF	Virtual	
E-poster EPA0002	Andreatta, K	PREEXISTING AND POSTBASELINE RESISTANCE ANALYSES IN POOLED PEDIATRIC STUDIES OF EMTRICITABINE/TENOFOVIR ALAFENAMIDE (F/TAF)-BASED ANTIRETROVIRAL THERAPY (ART)	Virtual	
E-poster EPB0235	Natukunda, E	WEIGHT CHANGE AND METABOLIC ASSESSMENT OF VIROLOGICALLY SUPPRESSED CHILDREN WITH HIV AGED ≥2 YEARS AND WEIGHING 14 TO <25 KG WHO RECEIVE A TAF-CONTAINING REGIMEN	Virtual	



HIV CURE				
Poster Exhibition	Zheng, Y TUPEB05	EVALUATION OF THERAPEUTIC CONCENTRATIONS OF ANTI-HIV ANTIBODIES 3BNC117/TEROPAVIMAB AND 10-1074/ZINLIRVIRMAB THROUGH PK-PD MODELING AND PREDICTION OF THE WASHOUT DURATION IN HIV CURE STUDIES	Tues, Jul 25 12:00-13:00 Poster Exhibition Area	
		PREVENTION		
E-poster EPC0319	Cox, S	EVALUATION OF CROSS-SECTIONAL HIV INCIDENCE RECENCY TESTING IN THE EVIDENCE FOR CONTRACEPTIVE OPTIONS AND HIV OUTCOMES (ECHO) TRIAL	Virtual	
		OTHER		
E-poster EPD0593	Cole, S	STIGMA AND POOR MENTAL WELLBEING: A GLOBAL COMMUNITY APPROACH TO IDENTIFYING AND ADDRESSING COMMON BARRIERS TO LIVING WELL WITH HIV	Virtual	



Investigator-Sponsored Research and Collaborative Studies: IAS 2023

Abstracts selected by Gilead Medical Affairs Germany, July 17th





B/F/TAF				
Oral / Poster	Presenter	Title	Session Information	Link to Session
Poster Exhibition TUPEB03	Ombajo, L.A	EFFICACY AND SAFETY OF SWITCHING OLDER ADULTS (≥60 YEARS) FROM FIRST- LINE ART TO B/F/TAF IN KENYA - A RANDOMIZED CLINICAL TRIAL (THE B/F/TAF ELDERLY STUDY)	Tues, Jul 25 12:00-13:00 Poster Exhibition area	
EPB0220	Bonnet, F	PROBABILITY OF SINGLE TABLET REGIMENS BIC/FTC/TAF, E/C/F/TAF, RPV/FTC/TAF, DTG/RPV OR DTG/ABC/3TC DISCONTINUATION AT 18 MONTHS IN REAL LIFE SETTINGS IN THE ANRS-CO3 - AQUIVIH-NA COHORT	Virtual	
E-poster EPB0210	Falistocco, C	EFFECTIVENESS AND SAFETY OF B/F/TAF FIXED-DOSE COMBINATION FOR THE TREATMENT OF PEOPLE LIVING WITH HIV IN ARGENTINA: FIRST INTERIM REPORT OF THE BICTARG COHORT	Virtual	
E-poster EPB0199	Severe, P	WEIGHT GAIN AND LIPID CHANGES WITH SWITCHING FROM BOOSTED PROTEASE INHIBITOR-BASED REGIMENS TO BICTEGRAVIR/TENOFOVIR ALAFENAMIDE/EMTRICITABINE	Virtual	
E-poster EPB0192	Rolle, C-P	96-WEEK UPDATE: CHANGE IN WEIGHT AND BMI ASSOCIATED WITH SWITCHING TO B/F/TAF VS. A DTG-BASED REGIMEN AMONG VIROLOGICALLY SUPPRESSED ADULTS LIVING WITH HIV	Virtual	
E-poster EPD0649	Lebouche, B	PSYCHOSOCIAL OUTCOMES FOR MIGRANTS IN A MULTIDISCIPLINARY HIV CLINIC WITH RAPID AND FREE B/F/TAF INITIATION: THE 'ASAP' STUDY	Virtual	8



Selected (elected Gilead-initiated/supported abstracts			S 2023	
	F/TAF				
Oral / Poster	Presenter	Title	Session Information	Link to Session	
E-poster EPB0247	Giaginto, C	UPTAKE AND OUTCOMES OF TENOFOVIR ALAFENAMIDE FUMARATE (TAF) -BASED THERAPY IN CHILDREN AND YOUNG PEOPLE LIVING WITH HIV (CLWHIV) IN THE EUROPEAN PREGNANCY AND PAEDIATRIC INFECTIONS COHORT COLLABORATION	Virtual		
		ACUTE HIV INFECTION & EARLY ART			
Poster Exhibition MOPEB01	Lee, S	RAPID TWO-PHASE DECAY OF INTACT AND DEFECTIVE HIV DNA DURING ACUTE TREATED HIV INFECTION, WHICH IS ACCELERATED WITH EARLIER ART INITIATION	Mon, Jul 24 12:00-13:00 Poster Exhibition area		
HIV AND HEPATITIS					
Oral OAB0303	Ananworanich, J	HIGH RATE OF HEPATITIS C AND REINFECTION AFTER DIRECT-ACTING ANTIVIRAL TREATMENT AMONG MEN-WHO-HAVE-SEX-WITH-MEN LIVING WITH HIV IN BANGKOK, THAILAND	Tues, Jul 25 16:11-16:19 Plaza Ballroom		





	COMORBIDITIES				
Oral / Poster	Presenter	Title	Session Information	Link to Session	
Oral (LB) OALBB05	Venter, F	RISKS OF HYPERTENSION WITH FIRST-LINE DOLUTEGRAVIR (DTG) AND TENOFOVIR ALAFENAMIDE (TAF) IN THE NAMSAL AND ADVANCE TRIALS	Tues, Jul 25 10:49-10:57 Great Hall		
E-poster EPB0169	Cozzi-Lepri, A	SELECTED COMORBIDITIES AND THE RISK OF ART SWITCH IN THE CONTEXT OF HIV- RNA SUPPRESSION	Virtual		
		WEIGHT/METABOLICS			
Oral (LB) OALBB0505	Lundgren, J	IMPACT OF INSTI AND TAF-RELATED BMI CHANGES AND RISK OF HYPERTENSION AND DYSLIPIDEMIA	Tues, Jul 25 10:57-11:05 Great Hall		
Oral OAB0402	Lundgren, J	INTEGRASE STRAND INHIBITORS (INSTI) RELATED CHANGES IN BMI AND RISK OF DIABETES	Wed, Jul 26 10:33-10:41 Plaza Ballroom		
E-poster EPD0571	Brennaning, M	PERSPECTIVES OF PEOPLE LIVING WITH HIV ON ART-RELATED WEIGHT CHANGE AND HEALTHY WEIGHT	Virtual		





	OTHER					
Oral / Poster	Presenter	Title	Session Information	Link to Session		
E-poster EPB0281	Ananworanich J	SEX AND SEXUALLY TRANSMITTED DISEASES IN TIME OF COVID: SEXUAL BEHAVIOR AND INCIDENCE OF GONORRHEA AND CHLAMYDIA IN AN HIV OBSERVATIONAL COHORT IN THAILAND	Virtual			





	HIV PREVENTION/PrEP				
Oral / Poster	Presenter	Title	Session Information	Link to Session	
Oral OAC0404	Phanuphak, N*	DRUG-DRUG INTERACTION BETWEEN FTC/TAF-BASED PREP AND FEMINIZING HORMONES IN TRANSGENDER WOMEN: PERIPHERAL BLOOD MONONUCLEAR CELLS AND URINE ANALYSIS FROM THE IFACT3 STUDY	Tues, Jul 25 16:19-16:27 Plaza Terrace		
E-poster EPB0205	Patel, N	THE RELATIONSHIP BETWEEN USE OF GENDER AFFIRMING THERAPIES AND TENOFOVIR DRIED BLOOD SPOT CONCENTRATIONS AMONG TRANSGENDER ADULTS SWITCHING FROM F/TDF TO F/TAF FOR PREP	Virtual		
E-poster EPB0217	Patel, N	THE RELATIONSHIP BETWEEN TENOFOVIR URINE AND DRIED BLOOD SPOT CONCENTRATIONS AMONG TRANSGENDER ADULTS SWITCHING FROM F/TDF TO F/TAF FOR PREP	Virtual		
E-poster EPC0434	Moodley, D	ASSESSING RENAL SAFETY OF DAILY ORAL F/TDF PRE-EXPOSURE PROPHYLAXIS IN PREGNANT AND LACTATING WOMEN: USING LOCALLY DEVELOPED NORMAL REFERENCE RANGES IN AN OPEN-LABEL RANDOMISED CONTROL STUDY	Virtual		





HIV PREVENTION/PrEP				
Oral / Poster	Presenter	Title	Session Information	Link to Session
E-poster EPE0819	Dobleck- Lewis, S	FEASIBILITY, ACCEPTABILITY, AND UPTAKE OF REMOTE PREP CARE IN A REAL- WORLD SETTING	Virtual	
Poster Exhibition TUPEE16	Hazra, A	PSYCHIATRISTS' ROLE IN ENDING THE HIV EPIDEMIC: A MIXED-METHODS INVESTIGATION OF KNOWLEDGE, PERCEIVED BARRIERS TO IMPLEMENTATION, AND TRAINING NEEDS TO SUPPORT PRE-EXPOSURE PROPHYLAXIS (PREP) PRESCRIPTION BY PSYCHIATRISTS	Tues, Jul 25 12:00-13:00 Poster Exhibition area	
E-poster EPC0371	Braun, R*	THE PREPTECH2 STUDY: A RANDOMIZED CONTROL TRIAL TO ASSESS THE IMPACT OF A TELEHEALTH PREP CARE INTERVENTION ON PREP UPTAKE AMONG YOUNG MSM AND TRANSGENDER WOMEN IN CALIFORNIA AND FLORIDA	Virtual	
E-poster EPE0793	Braun, R	ACCEPTABILITY OF A TELEHEALTH PREP DELIVERY PROGRAM FOR YOUNG MEN WHO HAVE SEX WITH MEN AND TRANSGENDER WOMEN IN CALIFORNIA AND FLORIDA, USA	Virtual	
Poster Exhibition MOPED22	Celum, C	HOPING TO ADHERE? EXAMINING THE RELATIONSHIP BETWEEN HOPE AND PREP WILLINGNESS AND ADHERENCE AMONG ADOLESCENT GIRLS AND YOUNG WOMEN ENROLLED IN HPTN 082	Mon, Jul 24 12:00-13:00 Poster Exhibition area	





HIV PREVENTION/PrEP				
Oral / Poster	Presenter	Title	Session Information	Link to Session
E-poster EPE1008	Sherer, R	PREP USE BEHAVIORS AND SEXUAL HEALTH IN CHINA DURING COVID-19 LOCKDOWNS	Virtual	
Poster Exhibition (LB) LBPED03	Bula, A	" SHOULD I HAVE MY NOSE CLOSE TO HIS?": PERSPECTIVES ON THE EFFECTS OF COVID-19 ON CLINICAL TRIAL PARTICIPATION AND HIV RISK AMONG WOMEN IN HPTN 084	Mon, Jul 24 12:00-13:00 Poster Exhibition area	
Oral (LB) OALBX0202	Hosseinipour, M	POSITIVE PREDICTIVE VALUE OF HIV SEROLOGICAL TESTS IN HPTN 084 TRIAL	Wed, Jul 26 12:03-12:11 Great Hall	
Oral (LB) OALBX0203	Moretlwe, S	INITIAL PREP PRODUCT CHOICE: RESULTS FROM HPTN 084 OPEN-LABEL EXTENSION	Wed, Jul 26 12:11-12:19 Great Hall	
E-poster (LB) LBEPE42	Abougi, L	ADOLESCENT AND YOUNG ADULT PREFERENCES FOR PREP SERVICE DELIVERY MODELS AND FORMULATIONS IN COLORADO, USA	Virtual	





HIV CURE				
Oral / Poster	Presenter	Title	Session Information	Link to Session
E-Poster (LB) LBEPB20	Mothe, B	T-CELL RESPONSES INDUCED BY HTI VACCINES AND VESATOLIMOD CORRELATE WITH IMPROVED CONTROL OF HIV REBOUND	Virtual	
E-poster EPA0080	Solis Leal, A	EFFECT OF COMBINATION LATENCY REVERSING AGENTS AND BNAB IN SHIV- INFECTED RHESUS MACAQUES ON ANTIRETROVIRAL THERAPY	Virtual	